The results indicated that high expression of KCNK9 (HR=1.7, 95% CI: 1.2-2.41, and p=0.0027) was associated with a shorter overall survival (OS) rate in the HCC patients while low expression of KCNK2 (HR=0.59, 95% CI: 0.41-0.84, and p=0.0033), KCNK15(HR=0.68, 95% CI: 0.48-0.98, and p=0.036), and KCNK17(HR=0.54, 95% CI: 0.38-0.77, and p=0.00055) was associated with a longer OS rate. This evidence concerns the gene KCNK2 and hepatocellular carcinoma.